Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12604172 | 0.91 | SLC6A2 (0.41) | MEN1KMT2ASLC6A2GAAPTPN1 | |
| SCHEMBL12604193 | 0.87 | MEN1 (0.43) | MEN1KMT2ASLC6A2 | |
| SCHEMBL12604168 | 0.85 | PTPN1 (0.42) | MEN1KMT2ASLC6A2PTPN1 | |
| SCHEMBL12604249 | 0.82 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL12650357 | 0.82 | ACHE (0.41) | MEN1KMT2ASLC6A2ACHEGAA | |
| SCHEMBL12604211 | 0.78 | KMT2A (0.45) | MEN1KMT2A | |
| SCHEMBL21852882 | 0.74 | MEN1 (0.65) | MEN1KMT2ASLC6A2PTPN1 | |
| SCHEMBL12650543 | 0.73 | SLC6A2 (0.37) | MEN1KMT2ASLC6A2ACHECDK1 | |
| SCHEMBL12798049 | 0.73 | SLC6A2 (0.37) | MEN1KMT2ASLC6A2ACHECDK1 | |
| SCHEMBL1294026 | 0.73 | KMT2A (0.53) | MEN1KMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987216-B2 | Polysulfated glycosides and salts thereof | Teva Hungary Pharmaceutical Marketing Private Limited Company (HU) | 2015-03-24 | — | — | US | disclosed |
| US-20110118198-A1 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | IVAX DRUG RESEARCH INSTITUTE LTD. (HU) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118198-A1 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF | CFTR, AREG, STS | MEN1 4865/4885KMT2A 3112/4885SLC6A2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.